| Popis: |
China's Growth Enterprise Market (GEM) debuted on the international stage on October 30, 2009. As the main force of the ChiNext board, biopharmaceutical companies have been committed to the research and development of innovative drugs unlike traditional pharmaceutical companies that only do generic drugs, and because of this, the value evaluation of such enterprises will change to a certain extent. Such enterprises will turn more to value creation in their business models, and corporate integration will also be improved, which will lead to a further increase in mergers and acquisitions of GEM pharmaceutical companies, and these changes will also make the demand for valuation of biomedical companies listed on the GEM continue to increase. In this context, this paper combines various factors and decides to select Betta Pharmaceutical as a case to evaluate the value of the enterprise. The research in this paper has important practical significance for restricting the development of the industry. |
